RNAC Stock Forecast & Price Target

Cartesian Therapeutics Inc. has demonstrated a positive trajectory with its innovative Descartes-08 therapy, showing substantial clinical improvements as evidenced by the recent Phase 2b data, which reported a significant average reduction of 4.8 in the MG-ADL scale at 12-month dosing intervals. The therapy's favorable safety profile, marked by the absence of severe adverse effects and consistent tolerability, enhances its potential for wider adoption among patients with autoimmune conditions, particularly among biologic-naive individuals. Additionally, the strong mechanistic data, including significant reductions in various cytokines linked to autoimmune responses, further substantiates the therapy's differentiated approach compared to traditional DNA-based CAR-T therapies, positioning Cartesian Therapeutics favorably within the biopharmaceutical landscape.

The financial outlook for Cartesian Therapeutics is concerning due to a notable decline in cash reserves from $162.1 million in 2Q25 to $145.1 million in 3Q25, raising questions about the sustainability of operations as the company prepares for its Phase 3 MG program. Despite reaching a market cap of under $200 million and a cash balance that suggests a low enterprise value, investors appear to assign minimal value to the Descartes-08 candidate for myasthenia gravis, which is magnified by a revised terminal growth rate cut from 3% to 1%. Furthermore, the burden of treatment due to the need for multiple cycles and high costs, combined with inadequate uptake among a significant number of patients, highlights ongoing challenges for the company’s financial performance and growth potential.